Associated Papers
Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans.
Telisnor G et al.
Journal of the National Medical Association, 2023
Circulating messenger RNA variants as a potential biomarker for surveillance of hepatocellular carcinoma.
Block T et al.
Frontiers in Oncology, 2022
36582804 (PubMed )
Supplement: Table_5.xlsx › Sheet1
An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.
Rha SY et al.
The Oncologist, 2007
Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
Kwon WS et al.
Pharmacogenetics and Genomics, 2006
Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway.
Fukunaga AK et al.
The Pharmacogenomics Journal, 2004
Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients.
Wong AL et al.
Cancer Genomics & Proteomics, 0
Select a paper to view details